Zydus Lifesciences Limited
ZYDUSLIFE
Hisse Senetlerindeki Sıralama
#1750
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Hisse Fiyatı
$12.30
Piyasa Değeri
$12.27B
Değişim (1 gün)
0.06%
Değişim (1 yıl)
8.33%
Ülke
IN
Ticaret Zydus Lifesciences Limited (ZYDUSLIFE)
Kategori
Healthcare
Zydus Lifesciences Limited (ZYDUSLIFE) için kazanç
Jun 2026 itibarıyla kazanç TTM: $674.03M
Zydus Lifesciences Limited şirketinin en son finansal raporlarına göre, mevcut kazancı $674.03M'dir. 2024 yılında şirket $590.92M kazanç elde etti, bu 2023 yılındaki $326.63M kazanca göre önceki yıla göre artış. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Zydus Lifesciences Limited için kazanç geçmişi 2004 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $674.03M | -5.26% |
| 2025 | $711.42M | 20.39% |
| 2024 | $590.92M | 80.91% |
| 2023 | $326.63M | -14.04% |
| 2022 | $379.97M | 13.69% |
| 2021 | $334.22M | 65.19% |
| 2020 | $202.32M | -42.16% |
| 2019 | $349.80M | -4.85% |
| 2018 | $367.62M | 44.63% |
| 2017 | $254.19M | -21.37% |
| 2016 | $323.28M | 39.35% |
| 2015 | $231.99M | 47.59% |
| 2014 | $157.19M | 5.61% |
| 2013 | $148.84M | -4.97% |
| 2012 | $156.62M | -17.15% |
| 2011 | $189.05M | 40.60% |
| 2010 | $134.46M | 84.59% |
| 2009 | $72.84M | -9.87% |
| 2008 | $80.82M | 27.90% |
| 2007 | $63.19M | 59.18% |
| 2006 | $39.70M | 26.43% |
| 2005 | $31.40M | -10.04% |
| 2004 | $34.90M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 161.79% |
IN
|
